Answers are grounded in this paper and cite their sources.
Purpose Based on the presence of early satiety in anorexia nervosa (AN), which may delay recovery, and given the dramatic impact of GLP-1 and GIP analog treatment on satiety and weight reduction in obesity by diminishing the sensation of hunger, we initiated this cross-sectional pilot study to explore fasting incretin levels in AN and to identify possible correlations between these hormones and psychiatric symptoms. Methods 17 female subjects aged 18–35 were enrolled; 10 previously diagnosed with AN (5 weight restored, 5 non-weight restored) and 7 healthy controls (HC). Fasting blood samples were analyzed for incretin levels using ELISA. Psychiatric symptoms were evaluated using self-assessment scales for eating disorders (EDI-3, EDE-Q), anxiety (STAI-S + T), depression (MADRS-S), and obsessive–compulsive disorder (OCI-R). Results Subjects with AN scored overall higher on psychiatric scales, indicating poorer psychological well-being than HC. In non-weight restored AN (non-WRAN) subjects both serum GLP-1 levels (29 (15–85) vs 16 (15–21) pg/mL; p = 0.048) as well as serum GIP levels (37 (14–163) vs 5 (2–58) pmol/L; p = 0.048) were elevated compared to HC. No differences were found in glucagon or PYY levels between groups. A strong correlation between serum GLP-1 levels and EDI-perfectionism independent of BMI (r = 0.768, p = 0.001) was found in the entire group. Conclusions Independent of BMI, GLP-1 levels were associated with perfectionism, a typical characteristic of AN. Fasting GLP-1 levels were elevated in subjects with non-WRAN. Elevated GLP-1 levels may perpetuate AN symptoms, emphasizing the need for further research into their role in the metabolic and psychiatric dimensions of AN. Level of evidence : Level III: Evidence obtained from well-designed case–control analytic studies.
No takes yet. Share an insight, caveat, or question.
Elm et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: